Literature DB >> 20963798

Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells.

M N Triba1, A Starzec, N Bouchemal, E Guenin, G Y Perret, L Le Moyec.   

Abstract

The metabolomic profiles of B16 melanoma cells were investigated in vitro with high resolution-magic angle spinning proton magnetic resonance spectroscopy and OPLS multivariate statistical analyse. We compared the profiles for untreated melanoma B16-F10 cells and Ca(2+) chelating EGTA, doxorubicin or BP7033 bisphosphonate treated cells. The two last molecules are known to induce anti-proliferative effects by different mechanisms of action in cells. Untreated and EGTA treated cells had similar profiles and were considered together as control cells. Several spectral regions could discriminate control from doxorubicin as well as BP7033 treated cells. Doxorubicin and BP7033 displayed distinct metabolic profiles. Important changes in neutral lipids and inositol were related to doxorubicin activity whereas BP7033 affected essentially phospholipids and alanine/lactate metabolism. These results provide new putative targets for both drugs. Metabolomics by NMR is shown here to be a good tool for the investigation of the mechanisms of action of drugs in pre-clinical studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963798     DOI: 10.1002/nbm.1516

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  9 in total

1.  1H NMR Metabolomics Study of Metastatic Melanoma in C57BL/6J Mouse Spleen.

Authors:  Xuan Wang; Mary Hu; Ju Feng; Maili Liu; Jian Zhi Hu
Journal:  Metabolomics       Date:  2014-12       Impact factor: 4.290

2.  Cold adaptation shapes the robustness of metabolic networks in Drosophila melanogaster.

Authors:  Caroline M Williams; Miki Watanabe; Mario R Guarracino; Maria B Ferraro; Arthur S Edison; Theodore J Morgan; Arezue F B Boroujerdi; Daniel A Hahn
Journal:  Evolution       Date:  2014-11-20       Impact factor: 3.694

3.  The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?

Authors:  Marie S A Palmnas; Hans J Vogel
Journal:  Metabolites       Date:  2013-05-17

4.  Studies of Secondary Melanoma on C57BL/6J Mouse Liver Using 1H NMR Metabolomics.

Authors:  Ju Feng; Nancy G Isern; Sarah D Burton; Jian Zhi Hu
Journal:  Metabolites       Date:  2013-10-31

5.  Metabolic impact of anti-angiogenic agents on U87 glioma cells.

Authors:  Tanja Mesti; Philippe Savarin; Mohamed N Triba; Laurence Le Moyec; Janja Ocvirk; Claire Banissi; Antoine F Carpentier
Journal:  PLoS One       Date:  2014-06-12       Impact factor: 3.240

6.  Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.

Authors:  Tanja Mesti; Nadia Bouchemal; Claire Banissi; Mohamed N Triba; Carole Marbeuf-Gueye; Maja Cemazar; Laurence Le Moyec; Antoine F Carpentier; Philippe Savarin; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2018-11-26       Impact factor: 2.991

7.  Metabolism under hypoxia in Tm1 murine melanoma cells is affected by the presence of galectin-3, a metabolomics approach.

Authors:  Pedro Starzynski Bacchi; Antonio Carlos Bloise; Silvina Odete Bustos; Lara Zimmermann; Roger Chammas; Said Rahnamaye Rabbani
Journal:  Springerplus       Date:  2014-08-26

8.  Metabolic Profiling Comparison of Human Pancreatic Ductal Epithelial Cells and Three Pancreatic Cancer Cell Lines using NMR Based Metabonomics.

Authors:  Miki Watanabe; Sulaiman Sheriff; Kenneth B Lewis; Junho Cho; Stuart L Tinch; Ambikaipakan Balasubramaniam; Michael A Kennedy
Journal:  J Mol Biomark Diagn       Date:  2012-03-12

9.  Response of Cisplatin Resistant Skov-3 Cells to [Pt(O,O'-Acac)(γ-Acac)(DMS)] Treatment Revealed by a Metabolomic ¹H-NMR Study.

Authors:  Federica De Castro; Michele Benedetti; Giovanna Antonaci; Laura Del Coco; Sandra Angelica De Pascali; Antonella Muscella; Santo Marsigliante; Francesco Paolo Fanizzi
Journal:  Molecules       Date:  2018-09-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.